The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows ...

The new biweekly dosing regimen for Tecvayli is intended for patients with RRMM who have achieved and maintained a complete response or better for a minimum of 6 months. The Food and Drug ...

(HealthDay News) — Bevacizumab is safe and stable when stored at 4 degrees Celsius, even with multiple dosing from a single vial, according to a study published in the July issue of Clinical & ...

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent ...

HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...

The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told BioSpace. Here are five therapies that could change the treatment paradigm.

C4 Therapeutics has learned a lot from just five multiple myeloma patients reporting out from the first cohort in a phase 1 trial of its lead candidate, a IKZF1/3 degrader called CFT7455. For starters ...

I was reminded of the issue recently when a physician colleague of mine treated an elderly man who presented with signs and ...